Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster
JAMA Neurology · 01.03.2023 · 80 (3) · 308
DOI: 10.1001/jamaneurol.2022.4804 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA Neurology, erschienen am 01.03.2023. Verfasst von Hans Christoph Diener und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Department of Neuroepidemiology, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Trigeminal Autonomic Cephalalgias, Cluster Headache, Paroxysmal Hemicrania. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
Importance Trigeminal autonomic cephalalgias (TACs) comprise a unique collection of primary headache disorders characterized by moderate or severe unilateral pain, localized in in the area of distribution of the first branch of the trigeminal nerve, accompanied by cranial autonomic symptoms and signs. Most TACs are rare diseases, which hampers the possibility of performing randomized clinical trials and large studies. Therefore, knowledge of treatment efficacy must be based only on observational studies, rare disease registries, and case reports, where real-world data and evidence play an important role in health care decisions. Observations Chronic cluster headache is the most common of these disorders, and the literature offers some evidence from randomized clinical trials to support the use of pharmacologic and neurostimulation treatments. Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, was not effective at 3 months in a randomized clinical trial but showed efficacy at 12 months in a large case series. For the other TACs (ie, paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms), only case reports and case series are available to guide physicians in everyday management. Conclusions and Relevance The accumulation of epidemiologic, pathophysiologic, natural history knowledge, and data from case series and small controlled trials, especially over the past 20 years from investigators around the world, has added to the previously limited evidence and has helped advance and inform the treatment approach to rare TACs, which can be extremely challenging for clinicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Department of Neuroepidemiology, University Duisburg-Essen, Essen, Germany.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- Headache Science & Neurorehabilitation Centre, IRCCS C., Mondino Foundation, Pavia, Italy.
- Department of Neurology, Mayo Clinic, Phoenix, Arizona.
- Atria Institute, New York, New York.
Zitieren
APA
Diener, H. C., Tassorelli, C., & Dodick, D. W. (2023). Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster. JAMA Neurology, 80(3), 308. https://doi.org/10.1001/jamaneurol.2022.4804
Vancouver
Diener HC, Tassorelli C, Dodick DW. Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster. JAMA Neurology. 2023;80(3):308. doi:10.1001/jamaneurol.2022.4804
BibTeX
@article{Diener2023,
author = {Diener, Hans Christoph and Tassorelli, Cristina and Dodick, David W},
title = {Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster},
journal = {JAMA Neurology},
year = {2023},
volume = {80},
number = {3},
pages = {308},
doi = {10.1001/jamaneurol.2022.4804}
}
EUVIMED